5Rosenstock J, Schwartz SL, Clark CM Jr, et al, Basa linsulin therapy in type 2 Diabetes: 28 - week comparison of insulin glargine ( HOM901 ) and NPH insulin. Diabetes Care 2001 ;24:631 -636.
6HU S, WANG S, FANELLI B, et al. Pancreatic beta- cellK (ATP) channel activity and membrane - binding studies with nateglinide : a comparison with sulfonylureas and repaglinide [ j ]. j Pharmacol Exp Ther 2000;293(2) :444 -452
7MR Rizzo, M Barbieri, R Grella, N Passariello, M Barone, G Paolisso Diabetes Metab 2004;30:81 -89.
8SIVITZ WI. Lipotoxicity and glucotoxicity in type 2 diabetes.Effects on development and progression [J]. Postgrad Med,2001,109 (4) :55 -59,63 -64.
9Matthews DR, Cull CA, Stratton IM, et al. UKPDS 26:Sulphonylurea failure in non -insulin -dependent diabetic patients over six years.UK Prospective Diabetes Study ( UKPDS) Group[J]. Diabet Meal,1998,15:297-303.
10Weyer. Dificiency in AIR predict IGT and Type 2 diabetes[J]. Diabetes Care,2001,24:89-94.
4O'Hagan C, De Vito G,Boreham CA.Exercise prescription in the treatment of type 2 diabetes mellitus: current prac rices,existing guidelines and future directions [J].Sports Med,2013,43(1) :39-49.
5Rosenstock J, Dailey G, Massi-Benedetti M,et a/.Reduced hypoglycemia risk with insulin glargine:a meta- analysiseomparing insulin glargine with human NPH insulin in type 2 diabeter~J].Diabetes Care,2005,28(4) :950-955.
6Monnier L, Lapinsbi H, Colette C ,et a/.Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic pa- tients:variations with increasing levels of HbAlc [J ]. Di- abetes Care ,2003,26(3 ) : 881-885.
